Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.

Vaccine - 8 Jun 2012

Vardas Eftyhia, Stanescu Ioana, Leinonen Mika, Ellefsen Kim, Pantaleo Giuseppe, Valtavaara Minna, Ustav Mart, Reijonen Kalevi

Abstract excerpt

BACKGROUND: Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the search for simpler, affordable HIV-1 treatment modalities. Therapeutic HIV-1 vaccines aim to provide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to AIDS Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Drug-Related Side Effects and Adverse Reactions

Share to Injections, Intramuscular

Share to Placebos

Share to Vaccines, DNA

Share to Vaccines, Synthetic

Source

Identifiers

PMID: 22549090
DOI: 10.1016/j.vaccine.2012.04.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.PMID 22549090Read ↗

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected AdultsSemantic proximity Read ↗

Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus AnkaraSemantic proximity Read ↗

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.Semantic proximity Read ↗

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersSemantic proximity Read ↗

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Semantic proximity Read ↗

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccineSemantic proximity Read ↗

HIV/AIDS Vaccines: 2018.Semantic proximity Read ↗

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian AdultsSemantic proximity Read ↗

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialSemantic proximity Read ↗

The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccineSemantic proximity Read ↗

HIV DNA Vaccine: Stepwise Improvements Make a DifferenceSemantic proximity Read ↗

Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.